Business
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, f
About this update from Spero Therapeutics, Inc.
[{"type":"image","alt":"Spero Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Spero Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NZ7Kj4X.syHvrTwbJDWHqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6fe4b8bd1b5673c609e8e3cb8c688861","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into Q2 2026 ","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":362,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.","length":376,"tagName":"p"},{"type":"text","content":""At Spero, our top priority remains the successful execution of the tebipenem HBr clinical program as we prepare for the pre-specified interim analysis of the PIVOT-PO trial during the second quarter,” said Esther Rajavelu, President and Chief Executive Officer. “We are developing tebipenem HBr to address the significant unmet need for an oral carbapenem option in the treatment of complicated urinary tract infections. We believe that, if approved, tebipenem HBr could deliver meaningful clinical and economic benefits, by improving patient outcomes and reducing the need for hospital stays.”","length":600,"tagName":"p"},{"type":"text","content":"Pipeline Update","length":15,"tagName":"p"},{"type":"text","content":"Tebipenem HBr","length":13,"tagName":"p"},{"type":"text","content":"Tebipenem HBr is an ...